Anish Sharda, MD, MPH
Assistant ProfessorCards
About
Research
Publications
2026
Seventh Åland Island Meeting on von Willebrand Disease
Lassila R, Bierings R, Connell N, Corrales‐Medina F, Federici A, Flood V, Heubel‐Moenen F, Johnsen J, Kuppens G, Matino D, Millar C, Schoen I, Sharda A, Sidonio R, Srivastava A, Szanto T, Weyand A, Berntorp E. Seventh Åland Island Meeting on von Willebrand Disease. Haemophilia 2026 PMID: 42126143, DOI: 10.1111/hae.70302.Peer-Reviewed Original ResearchVon Willebrand diseaseWillebrand diseaseClinical aspectsTreatment of von Willebrand diseaseDefinitions of disease severityBleeding disordersTreatment strategiesCare of peopleDiagnostic landscapeDisease severityLaboratory insightsMultidisciplinary approachClinical debateDiseaseClinical topicsTreatmentEmergency researchCareCorrection: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry
Pine A, Butt A, Andreoli L, Knight J, Gerosa M, Cecchi I, Branch D, Lopez-Pedrera R, Belmont H, Kello N, Petri M, Cervera R, Pengo V, Meroni P, Cohen H, Willis R, Bertolaccini M, Goshua G, Gu S, Hwa J, Lee A, Erkan D, Sharda A. Correction: A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry. Frontiers In Immunology 2026, 17: 1807468. PMID: 42039181, PMCID: PMC13107004, DOI: 10.3389/fimmu.2026.1807468.Commentaries, Editorials and LettersAnticoagulants and Thrombolytics
Mones J, Sharda A, Lech T, Zwicker J. Anticoagulants and Thrombolytics. 2026, 487-496. DOI: 10.1007/978-3-032-13858-3_47.Peer-Reviewed Original Research
2025
Platelet-related biomarkers and catheter-associated thrombosis in critically ill children: An exploratory study
Regmi H, Li I, Prozora S, Sharda A, Shabanova V, Faustino E, Investigators C. Platelet-related biomarkers and catheter-associated thrombosis in critically ill children: An exploratory study. Thrombosis Research 2025, 256: 109534. PMID: 41223722, PMCID: PMC12712714, DOI: 10.1016/j.thromres.2025.109534.Peer-Reviewed Original ResearchConceptsCatheter-associated deep venous thrombosisClinically Relevant BleedingCritically Ill ChildrenCentral venous catheterProphylactic enoxaparinPlatelet factor 4P-selectinIL-6Ill childrenTNF-aPlatelet activationBiomarkers of platelet activationCatheter-associated thrombosisDeep venous thrombosisFactor 4Platelet-poor plasmaSeverity of illnessRelevant bleedingPharmacological prophylaxisPlatelet countVenous cathetersMulticenter studyVenous thrombosisIL-2IL-1BA proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry
Pine A, Butt A, Andreoli L, Knight J, Gerosa M, Cecchi I, Branch D, Lopez-Pedrera R, Belmont H, Kello N, Petri M, Cervera R, Pengo V, Meroni P, Cohen H, Willis R, Bertolccini M, Goshua G, Gu S, Hwa J, Lee A, Erkan D, Sharda A. A proteomic map of thromboinflammatory signatures in antiphospholipid syndrome: results from antiphospholipid syndrome alliance for clinical trials and international networking (APS ACTION) registry. Frontiers In Immunology 2025, 16: 1676578. PMID: 41181143, PMCID: PMC12571811, DOI: 10.3389/fimmu.2025.1676578.Peer-Reviewed Original ResearchConceptsAntiphospholipid syndromeInflammatory signatureClinical trialsAdaptive immune response pathwaysPersistently aPL-positive patientsPathogenesis of antiphospholipid syndromeClinical antiphospholipid syndromePathophysiology of antiphospholipid syndromeAPL-positive patientsCirculating antiphospholipid antibodiesPresence of aPLAntiphospholipid syndrome classificationAdaptive immune activationActivation of coagulationStatistical significanceAntiPhospholipid Syndrome AllianceMultiple pathophysiological mechanismsObstetric morbidityAntiphospholipid antibodiesImmune response pathwaysImmune cellsImmune activationAutoimmune diseasesProteomic screenClinical severityEROdicating arterial thrombosis with a novel endoplasmic reticulum oxidoreductase 1α inhibitor
Yarovinsky T, Sharda A, Hwa J. EROdicating arterial thrombosis with a novel endoplasmic reticulum oxidoreductase 1α inhibitor. Molecular Therapy 2025, 33: 4682-4683. PMID: 40975058, PMCID: PMC12848167, DOI: 10.1016/j.ymthe.2025.09.012.Peer-Reviewed Original ResearchAnalytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome
Butt A, Sharda A, Lee A, Knight J. Analytical Review: Neutrophil Extracellular Traps and Antiphospholipid syndrome. Transfusion Medicine Reviews 2025, 40: 150909. PMID: 40783311, DOI: 10.1016/j.tmrv.2025.150909.Peer-Reviewed Original ResearchNeutrophil extracellular trapsAntiphospholipid syndromeAdenosine A2A receptorNegative regulatorP-selectin glycoprotein ligand-1Anti-NET antibodiesInduction of NETosisTranscription factor KLF2Regulation of NETosisAutoimmune prothrombotic disorderDecondensed chromatinDevelopment of thrombosisElevated NET levelsNeutrophil-mediated mechanismsGranule proteinsComplement system activationActivated Protein CObstetric complicationsAntiphospholipid antibodiesProthrombotic disordersNeutrophil-derived granule proteinsThrombotic eventsThrombotic riskClinical manifestationsAutoimmune disordersRalB uncoupling from exocyst is required for endothelial Weibel-Palade body exocytosis
Yang M, Boye-Doe A, Ali M, Abosabie S, Barr A, Mendez L, Sharda A. RalB uncoupling from exocyst is required for endothelial Weibel-Palade body exocytosis. Molecular Biology Of The Cell 2025, 36: ar62. PMID: 40172988, PMCID: PMC12086567, DOI: 10.1091/mbc.e24-11-0493.Peer-Reviewed Original ResearchConceptsWeibel-Palade body exocytosisHypervariable regionWeibel-Palade bodiesC-terminal hypervariable regionHemostatic protein von Willebrand factorGDP-bound stateGTP-bound stateExocytosis of Weibel-Palade bodiesDegree of homologyRal isoformsEffector proteinsCell stimulationProtein kinase C (PKC)-dependent phosphorylationNonphosphorylatable mutantRal GTPasesExocystSite mutantsSerine residuesRas-likeCellular processesExocytosisRalBRegulate effectorsEndothelial secretory granulesSecretory granulesCongenital T-cell activation impairs transitional-to-follicular B-cell maturation in humans
Allard-Chamard H, Hillier K, Ramseier M, Bertocchi A, Kaneko N, Premo K, Yuen G, Karpel M, Mahajan V, Tsekeri C, Hong J, Vencic J, Crotty R, Sharda A, Barmettler S, Westermann-Clark E, Walter J, Ghebremichael M, Shalek A, Farmer J, Pillai S. Congenital T-cell activation impairs transitional-to-follicular B-cell maturation in humans. Blood Advances 2025, 9: 520-532. PMID: 39626280, PMCID: PMC11814514, DOI: 10.1182/bloodadvances.2024013267.Peer-Reviewed Original ResearchConceptsCytotoxic T-lymphocyte-associated protein 4B cell maturationRegulatory T cellsT cell activationT cellsMammalian target of rapamycin complex 1B cellsEffector CD4+ T cellsExcessive T cell activationFunctional regulatory T cellsCD4+ T cellsHumoral immune dysfunctionB cell defectsMammalian targetPatients lymph nodesTransitional B cellsB cell stageB cell developmentCell-to-cell contactCD27- B cellsMammalian target of rapamycin complex 1 signalingCD40L levelsImmune dysfunctionReplacement therapyLymph nodes
2024
CRE24-052: Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic Challenge
Lobo A, Zengin Z, Kenworthy C, Sharda A. CRE24-052: Hyperfibrinolysis as the Primary Presenting Sign of Metastatic Prostate Cancer: A Diagnostic Challenge. Journal Of The National Comprehensive Cancer Network 2024, 22 DOI: 10.6004/jnccn.2023.7326.Peer-Reviewed Original Research
Academic Achievements & Community Involvement
Clinical Care
Overview
Anish Sharda, MBBS (a medical degree awarded outside of the U.S.), is a physician-scientist and an assistant professor of medicine at Yale School of Medicine. Dr Sharda is a classical hematologist who specializes in the treatment of bleeding, clotting, and platelet disorders.
Dr. Sharda runs a National Institutes of Health-funded laboratory that conducts research in bleeding and clotting disorders, specifically von Willebrand disease. His research aims to improve understanding of this bleeding disorder as well as discover novel treatments.
Dr. Sharda completed his medical training at B.P. Koirala Institute of Health Sciences in Nepal, followed by a residency in internal medicine at the University of Minnesota Medical Center. He then pursued a clinical and research fellowship in hematology and oncology at Beth Israel Deaconess Medical Center and Harvard Medical School, where he was a faculty member until 2022.
Clinical Specialties
Hematology
Fact Sheets
Bleeding Disorders
Learn More on Yale MedicineBlood Clots in Veins, Heart and Lungs
Learn More on Yale Medicine
Yale Medicine News
News & Links
Media
Smilow Shares with Primary Care: Benign Hematology and Elevated Blood Counts
January 7, 2025
Presentations by: Frank Ciminiello, MD, Kelsey Martin, MD, and Anish Sharda, MD, MPH
News
- July 06, 2026
Dr. Mohammed Ali Receives 2026 JH Milstone Award in Hematology
- January 08, 2025
Smilow Shares with Primary Care: Benign Hematology and Elevated Blood Counts
- February 15, 2024
Educational Exchange Brings Ugandan Hematologist Dr. Christine Sekaggya-Wiltshire to Yale School of Medicine
- December 08, 2023
New Research Reveals How Modifying a Key Molecular Regulator Could Improve the Treatment of von Willebrand Disease
Get In Touch
Contacts
Appointment Number
Mailing Address
Hematology
300 George St
New Haven, Connecticut 06511
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.